NCT06850727Phase 2Recruiting

Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-04Estimated

Enrollment · participants57Estimated

Source updated2026-02-11Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-02-11 · 1 field changed

Primary completion date changed

− Before

~~Jan 2026~~

+ After

Apr 2026

Check registry source

Study details

Conditions studied

Ulcerative Colitis (UC); UC - Ulcerative Colitis

Treatments or interventions studied

OD-07656Drug
VedolizumabDrug

Primary outcomes · main study measures

Read the study measures

measure: Change in 3-component modified Mayo Clinic Score (MMCS) from baseline to after treatment with OD-07656; description: The 3-component MMCS ranges from 0 to 9 and is composed of endoscopic assessment, rectal bleeding and stool frequency subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease.; timeFrame: Baseline and 12 weeks; measure: Incidence of treatment-emergent adverse events (TEAEs) and treatment discontinuations due to TEAEs with OD-07656 treatment; timeFrame: Up to 12 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history